Riskpilot← Back to searchSign inGet full accessPRIMEX BIOCHEMICALS AS
ASActiveOrg 882795322Sørhauggata 217, 5525 HaugesundManufacture of other food products n.e.c. · NACE 1089Est. 20012 employees
Revenue 2024
NOK 1,1M
-53% vs 2023
EBITDA margin
-13.3%
-184% vs 2023
Equity ratio
43.9%
Financial strength
Net profit 2024
NOK -301K
-742% vs 2023
| Revenue | NOK 1,1M | -53% |
| EBITDA | NOK -146K | -184% |
| Net profit | NOK -301K | -742% |
| Total assets | NOK 2,9M | -22% |
| Equity | NOK 1,3M | -19% |
| Employees | 2 | — |
Legal name
PRIMEX BIOCHEMICALS AS
Org number
882795322
Legal form
Aksjeselskap
NACE code
1089 · Manufacture of other food products n.e.c.
Founded
5. januar 2001
Share capital
NOK 1 000 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og nestleder hver for seg.
Company purpose
Drive produksjon, forskning, utvikling og handel knyttet til ingredienser fremstilt av marine råstoffer og biprodukter.
Address
Sørhauggata 217, 5525 Haugesund
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 050 | 2 808 | 1 675 | 2 346 | 1 097 |
| Staff expenses | −831 | −713 | −271 | −152 | −175 |
| EBITDA | −126 | 749 | −254 | 174 | −146 |
| Depreciation & amort. | −10 | −29 | −26 | −28 | −31 |
| EBIT | −136 | 720 | −280 | 146 | −177 |
| Net financials | −82 | −85 | −87 | −99 | −124 |
| Profit before tax | −218 | 635 | −367 | 47 | −301 |
| Tax | −0 | −18 | −0 | −0 | −0 |
| Net profit | −218 | 653 | −367 | 47 | −301 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 286 | 4 913 | 3 990 | 3 711 | 2 879 |
| Equity | 1 582 | 2 235 | 1 868 | 1 565 | 1 264 |
| Long-term debt | 1 403 | 1 284 | 1 163 | 1 045 | 920 |
| Short-term debt | 1 301 | 1 394 | 959 | 1 101 | 695 |
| Total debt | 2 704 | 2 678 | 2 122 | 2 146 | 1 615 |
EBITDA margin
-13.3%
This company
15.8%
Market median
-184% vs market
20202024
Equity ratio
43.9%
This company
38.2%
Market median
+15% vs market
20202024
Return on equity
-23.8%
This company
18.4%
Market median
-229% vs market
20202024
Net profit margin
-27.4%
This company
8.1%
Market median
-438% vs market
20202024
Asset turnover
0.38×
This company
1.12×
Market median
-66% vs market
20202024
Debt / equity
1.28×
This company
0.62×
Market median
-106% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SI Deputy Member | Deputy Member | 2012 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2012 | |
| Board of Directors | 2012 | |
| Board of Directors | 2012 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Anmara As
PRIMEX BIOCHEMICALS AS Board members of PRIMEX BIOCHEMICALS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Svein Ivar Langhelle | Deputy Member | 0 companies |
| Thore Ivar Thorsen | Chairman | 0 companies |
| Raymond Olsen | Board of Directors | 0 companies |
| Raymond Bravo Olsen | Board of Directors | 0 companies |